Stephen M Clark
Overview
Explore the profile of Stephen M Clark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mort J, Brighton D, DiBenedetto S, Wells L, Clark S, Reid J, et al.
Eur J Haematol
. 2024 Nov;
114(3):481-494.
PMID: 39601208
Gemtuzumab ozogamicin (GO) is a CD33-targeting antibody-drug conjugate approved for the treatment of CD33-positive de novo and relapsed and refractory acute myeloid leukemia (AML). Subset analyses have demonstrated improved clinical...
2.
Fentie A, Mekonen Z, Gizachew Z, Hailemariam M, Clark S, Richardson J, et al.
Pediatr Hematol Oncol
. 2022 Oct;
40(3):258-266.
PMID: 36308760
Optimal chemotherapy management is substandard in low and middle-income countries. We aimed to identify major gaps to design interventional strategies for improved chemotherapy management at Tikur Anbessa Specialized Hospital (TASH),...
3.
Stocker K, Tiemann A, Brunk K, Agegnehu B, Buhlinger K, Amerine L, et al.
J Oncol Pharm Pract
. 2022 Oct;
29(7):1555-1564.
PMID: 36303425
Background: The impact and downstream effects of the chemotherapy supply chain in Ethiopia are not well understood. The purpose of this study was to identify perceived gaps in supply chain...
4.
Levy S, Fentie A, Buhlinger K, Clark S, Korones D, Miller V, et al.
Arch Dis Child
. 2021 Jun;
106(12):1244-1245.
PMID: 34140309
No abstract available.
5.
Buhlinger K, Borlagdan J, Agegnehu B, Fentie A, Bernstein A, Urick B, et al.
J Oncol Pharm Pract
. 2020 Dec;
27(8):1940-1947.
PMID: 33342356
In Ethiopia, cancer accounts for about 5.8% of total national mortality, with an estimated annual incidence of cancer of approximately 60,960 cases and an annual mortality of over 44,000 persons....
6.
Palmer S, Tillman 3rd F, Sharma P, Auten J, Owen K, Clark S, et al.
Ann Pharmacother
. 2020 Aug;
55(3):303-310.
PMID: 32847379
Background: Although intravenous (IV) bisphosphonates are first-line medications for the management of hypercalcemia, studies examining their use in patients with preexisting renal dysfunction are limited. Objective: The objective of this...
7.
Sebring E, Rudisill M, Bates J, Auten J, Urick B, Clark S
J Manag Care Spec Pharm
. 2020 May;
26(6):723-727.
PMID: 32463774
Background: The North Carolina Cancer Hospital at the University of North Carolina Medical Center serves patients with a variety of malignant conditions and discharges more than 130 patients each month....
8.
Malpica L, Mufuka B, Galeotti J, Tan X, Grover N, Clark S, et al.
Leuk Lymphoma
. 2020 Feb;
61(6):1508-1511.
PMID: 32037934
No abstract available.
9.
Rich J, Clark S, Fedoriw Y, Jewells V, Wood W, Dittus C
Clin Case Rep
. 2019 Oct;
7(10):1957-1961.
PMID: 31624617
Central nervous system (CNS)-relapsed mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non-Hodgkin lymphomas...
10.
Lentz K, Clark S, Ayarza M, Liu B, Morgan K, Wind L, et al.
J Oncol Pharm Pract
. 2019 Jul;
26(2):406-412.
PMID: 31288633
Study Objective: To determine whether thiamine prophylaxis decreases the incidence of ifosfamide-induced encephalopathy in patients receiving ifosfamide for the treatment of lymphoma. Design: Retrospective, multi-center, cohort study. Patients: A total...